CRISPR THERAPEUTICS AG (CRSP) — insider trading
Health Care · NASDAQ
CRISPR THERAPEUTICS AG (CRSP) has 12 reported SEC Form 4 insider transactions in our data (latest 2026-06-05).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-05 | Treco Douglas A | Director | Grant / award / vesting (derivative) | 13,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Rommel Christian | Director | Grant / award / vesting (derivative) | 13,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Morrison Briggs | Director | Grant / award / vesting (derivative) | 13,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Mahatme Sandesh | Director | Grant / award / vesting (derivative) | 13,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | High Katherine A | Director | Grant / award / vesting (derivative) | 13,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Greene John | Director | Grant / award / vesting (derivative) | 13,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Fleming Harold Edward | Director | Grant / award / vesting (derivative) | 13,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Fardis Maria | Director | Grant / award / vesting (derivative) | 13,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Behbahani Ali | Director | Grant / award / vesting (derivative) | 13,000 | $0.00 | $0 | Form 4 |
| 2026-06-05 | George Simeon | Director | Grant / award / vesting (derivative) | 13,000 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Patel Naimish | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 22,000 | $0.00 | $0 | Form 4 |
| 2026-05-29 | KASINGER JAMES R. | Officer (General Counsel and Secretary) | Grant / award / vesting (derivative) | 17,000 | $0.00 | $0 | Form 4 |
Ask the chat about CRSP's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: CRISPR THERAPEUTICS AG (CRSP).
Last updated 2026-06-05 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.